Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nxera Snags US$10 Million Milestone from AbbVie in Neurology Collab
June 28, 2024
- FDA Snubs Daiichi Sankyo’s HER3 ADC over Third-Party Manufacturing Issue
June 28, 2024
- Takeda Files Alagille Syndrome Drug Maralixibat in Japan
June 28, 2024
- Ayumi Taps Ex-Ferring Japan CEO as New President
June 28, 2024
- Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
June 27, 2024
- Jugo Tsumura to Step Down as Ferring Japan CEO
June 27, 2024
- Takeda Targets 50% Female Ratio for Board of Directors: CEO
June 27, 2024
- Takeda CEO’s Pay Tops 2 Billion Yen in FY2023
June 27, 2024
- TGCV Drug CNT-01 Misses Goal in Japan PIIb/III Study: Toa Eiyo
June 26, 2024
- Tagrisso Plus Chemo Now Allowed to Treat EGFR Lung Cancer: AstraZeneca
June 26, 2024
- JCR, Takeda End Global Collab for Hunter Syndrome Therapy
June 26, 2024
- Rexulti’s PTSD Filing Clinches FDA Acceptance for Review: Otsuka/Lundbeck
June 26, 2024
- Santen CEO Snares 191 Million Yen in Annual Pay, Workforce Down by 131
June 26, 2024
- Finnish Pharma Orion Poised for Japan Debut with Reacquisition of Parkinson’s Meds This Year
June 26, 2024
- AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
June 25, 2024
- Recordati Japan Names Shoji Kuroyama as New President
June 25, 2024
- Takeda Scores EU Approval for Colorectal Cancer Med Fruzaqla
June 25, 2024
- BMS Gears Up for Return to Neuroscience with KarXT, Explores Path toward Japan Rollout Too
June 25, 2024
- Shionogi Workforce Down 341 after Voluntary Buyout Program
June 24, 2024
- Axcelead’s Next CEO Eyes Sales of 120 Billion Yen, Ramp-Up in Mega Pharma Orders
June 21, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…